Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients

Next Previous
Trial Profile

A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EPIC 321 (Primary)
  • Indications Facioscapulohumeral muscular dystrophy
  • Focus Adverse reactions; First in man
  • Sponsors EPIC BIO; Epicrispr Biotechnologies

Most Recent Events

  • 13 Jan 2026 According to an Epicrispr Biotechnologies media release, the company reported early clinical data from an ongoing first-in-human, open-label study evaluating EPI-321 for facioscapulohumeral muscular dystrophy (FSHD). To date, three participants have completed their three-month follow-up visits. The study remains ongoing, with plans to continue enrolling participants and to further evaluate safety and exploratory efficacy outcomes over time.
  • 13 Jan 2026 According to an Epicrispr Biotechnologies media release, company received approval for CTA application for phase I/II trial in facioscapulohumeral muscular dystrophy in New Zealand and Australia before January 2025.
  • 08 Jan 2026 Results presented in an Epicrispr Biotechnologies media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top